Oncotherm

The company's methodology is based on the view of its founder that the heat-dose sensitive characterization of tissue is at the core of the oncothermia treatment.^[1] The tumor tissue has lower impedance than the surrounding tissues,^{[citation needed]} so most of the energy is transmitted and absorbed by the cancerous lesion. This selection of the tumor tissues (self-focusing) renders external focusing unnecessary.^[2]

Oncotherm Ltd. was founded in 1988 by Prof. Dr. András Szász^[3] in Hungary. In 2002, it received investment from a German company and was reorganized as a German-Hungarian company consisting of Oncotherm Hungary Ltd^[4] and Oncotherm GmbH.^[5]

Their main products are the Oncotherm EHY-2000^[6] and the Oncotherm EHY-2030,^[7] hyperthermia devices using the thermoelectric effects of electrical fields.

More than 450 devices have been placed into operation, mostly in Germany and South Korea, and performed over 400,000 treatments.^[8] The devices are not approved by the U.S. Food and Drug Administration.^{[citation needed]}